Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
28 nov. 2023 08h06 HE
|
Sol-Gel Technologies Ltd.
Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial ...
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
09 nov. 2023 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023Gorlin Syndrome KOL event to be held on December 6, 2023Sol-Gel maintains...
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
30 août 2023 08h00 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients...
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
10 août 2023 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Sol-Gel’s recently announced agreement with Searchlight Pharma will...
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
06 juin 2023 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel to receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined, plus additional royalties ranging from low double-digits to...
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
12 mai 2023 07h00 HE
|
Sol-Gel Technologies Ltd.
Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610...
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
20 mars 2023 07h00 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an...
Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
10 mars 2023 07h00 HE
|
Sol-Gel Technologies Ltd.
Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in...
Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
27 janv. 2023 07h29 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two...
Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
27 janv. 2023 07h00 HE
|
Sol-Gel Technologies Ltd.
Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDAPhase 3...